amifostine anhydrous has been researched along with Adverse Drug Event in 15 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Melphalan was given in doses up to and including 300 mg/m(2)." | 2.71 | Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I study. ( Adams, VR; Badros, A; Brunner, J; Fenton, R; Filicko, J; Flomenberg, N; Grosso, D; Hale, GA; Howard, DS; Johnson, VP; Kniska, A; Marshall, KW; Meisenberg, B; Nath, R; Phillips, GL; Rapoport, AP; Reece, DE; Reed, E; Takebe, N; Vesole, DH; Wagner, JL, 2004) |
| "Oral mucositis is a common complication of cancer treatment that may negatively impact the patient's cancer treatment outcome." | 2.52 | Mucositis: pathobiology and management. ( Sonis, ST; Villa, A, 2015) |
| " We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts." | 1.37 | FDA-approved drug labeling for the study of drug-induced liver injury. ( Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011) |
| "5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects." | 1.32 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. ( Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (60.00) | 29.6817 |
| 2010's | 5 (33.33) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Matthews, EJ | 1 |
| Kruhlak, NL | 1 |
| Weaver, JL | 1 |
| Benz, RD | 1 |
| Contrera, JF | 1 |
| Chen, M | 1 |
| Vijay, V | 1 |
| Shi, Q | 2 |
| Liu, Z | 2 |
| Fang, H | 2 |
| Tong, W | 2 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Ji, L | 1 |
| Cui, P | 1 |
| Zhou, S | 1 |
| Qiu, L | 1 |
| Huang, H | 1 |
| Wang, C | 1 |
| Wang, J | 1 |
| Rohilla, S | 1 |
| Dureja, H | 1 |
| Chawla, V | 1 |
| Lawrence, YR | 1 |
| Paulus, R | 1 |
| Langer, C | 1 |
| Werner-Wasik, M | 1 |
| Buyyounouski, MK | 1 |
| Komaki, R | 1 |
| Machtay, M | 1 |
| Smith, C | 1 |
| Axelrod, RS | 1 |
| Wasserman, T | 1 |
| Bradley, JD | 1 |
| Movsas, B | 1 |
| Villa, A | 1 |
| Sonis, ST | 1 |
| Sharma, M | 1 |
| Vijayaraghavan, R | 1 |
| Gautam, A | 1 |
| Sagowski, C | 1 |
| Wenzel, S | 1 |
| Metternich, FU | 1 |
| Kehrl, W | 1 |
| Phillips, GL | 1 |
| Meisenberg, B | 1 |
| Reece, DE | 1 |
| Adams, VR | 1 |
| Badros, A | 1 |
| Brunner, J | 1 |
| Fenton, R | 1 |
| Filicko, J | 1 |
| Grosso, D | 1 |
| Hale, GA | 1 |
| Howard, DS | 1 |
| Johnson, VP | 1 |
| Kniska, A | 1 |
| Marshall, KW | 1 |
| Nath, R | 1 |
| Reed, E | 1 |
| Rapoport, AP | 1 |
| Takebe, N | 1 |
| Vesole, DH | 1 |
| Wagner, JL | 1 |
| Flomenberg, N | 1 |
| Thongprasert, S | 1 |
| Chewaskulyong, B | 1 |
| Asna, N | 1 |
| Lewy, H | 1 |
| Ashkenazi, IE | 1 |
| Deutsch, V | 1 |
| Peretz, H | 1 |
| Inbar, M | 1 |
| Ron, IG | 1 |
| Block, KI | 1 |
| Gyllenhaal, C | 1 |
| Alberts, DS | 1 |
| Delforge, A | 1 |
| Ozkaynak, MF | 1 |
| Sahdev, I | 1 |
| Gross, TG | 1 |
| Levine, JE | 1 |
| Cheerva, AC | 1 |
| Richards, MK | 1 |
| Rozans, MK | 1 |
| Shaw, PJ | 1 |
| Kadota, RP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III Randomized Study of Amifostine Mucosal Protection for Patients With Favorable Performance Inoperable Stage II-III A/B Non-Small Cell Lung Cancer (NSCLC) Receiving Sequential Induction and Concurrent Hyperfractionated Radiotherapy With Paclitax[NCT00003313] | Phase 3 | 243 participants (Actual) | Interventional | 1998-09-30 | Completed | ||
| The Effectiveness of Topical Oral Vitamin D Gel in Prevention of Radiation-induced Oral Mucositis[NCT04308161] | Phase 2 | 45 participants (Anticipated) | Interventional | 2019-11-02 | Recruiting | ||
| The Effectiveness of Melatonin in Prevention of Radiation-induced Oral Mucositis[NCT03833570] | Phase 2 | 40 participants (Actual) | Interventional | 2018-01-12 | Completed | ||
| Effect of Prophylactic Use of Oral Vitamin D and Zinc in Management of the Severity of Radiation Induced Oral Mucositis of Head and Neck Cancer Patients[NCT06100692] | 100 participants (Anticipated) | Observational | 2023-11-01 | Not yet recruiting | |||
| A Phase III Randomized Trial of Intravenous Paclitaxel and Cisplatin Versus Intravenous Paclitaxel, Intraperitoneal Cisplatin and Intraperitoneal Paclitaxel in Patients With Optimal Stage III Epithelial Ovarian Carcinoma or Primary Peritoneal Carcinoma[NCT00003322] | Phase 3 | 384 participants (Anticipated) | Interventional | 1998-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for amifostine anhydrous and Adverse Drug Event
| Article | Year |
|---|---|
Advances of Amifostine in Radiation Protection: Administration and Delivery.
Topics: Adjuvants, Immunologic; Administration, Intravenous; Amifostine; Drug-Related Side Effects and Adver | 2023 |
Cytoprotective Agents to Avoid Chemotherapy Induced Sideeffects on Normal Cells: A Review.
Topics: Amifostine; Antineoplastic Agents; Cytoprotection; Drug-Related Side Effects and Adverse Reactions; | 2019 |
Mucositis: pathobiology and management.
Topics: Amifostine; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Fibroblast Growt | 2015 |
Mucositis: pathobiology and management.
Topics: Amifostine; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Fibroblast Growt | 2015 |
Mucositis: pathobiology and management.
Topics: Amifostine; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Fibroblast Growt | 2015 |
Mucositis: pathobiology and management.
Topics: Amifostine; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Fibroblast Growt | 2015 |
Mucositis: pathobiology and management.
Topics: Amifostine; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Fibroblast Growt | 2015 |
Mucositis: pathobiology and management.
Topics: Amifostine; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Fibroblast Growt | 2015 |
Mucositis: pathobiology and management.
Topics: Amifostine; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Fibroblast Growt | 2015 |
Mucositis: pathobiology and management.
Topics: Amifostine; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Fibroblast Growt | 2015 |
Mucositis: pathobiology and management.
Topics: Amifostine; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Fibroblast Growt | 2015 |
Commentary: the pharmacological antioxidant amifostine -- implications of recent research for integrative cancer care.
Topics: Amifostine; Antioxidants; Clinical Trials as Topic; Combined Modality Therapy; Drug-Related Side Eff | 2005 |
Maximizing the delivery of intraperitoneal therapy while minimizing drug toxicity and maintaining quality of life.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug-Related S | 2006 |
4 trials available for amifostine anhydrous and Adverse Drug Event
| Article | Year |
|---|---|
The addition of amifostine to carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell lung cancer: long-term follow-up of Radiation Therapy Oncology Group (RTOG) randomized trial 9801.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carbopla | 2013 |
Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I study.
Topics: Adult; Aged; Amifostine; Cohort Studies; Disease-Free Survival; Drug-Related Side Effects and Advers | 2004 |
Study of cisplatin-vinblastine plus amifostine in patients with locally advanced or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cytoprote | 2004 |
A pilot study of addition of amifostine to melphalan, carboplatin, etoposide, and cyclophosphamide with autologous hematopoietic stem cell transplantation in pediatric solid tumors-A pediatric blood and marrow transplant consortium study.
Topics: Adolescent; Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplan | 2008 |
6 other studies available for amifostine anhydrous and Adverse Drug Event
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Dru | 2004 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Des | 2011 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
DRDE-07 and its analogues as promising cytoprotectants to nitrogen mustard (HN-2)--an alkylating anticancer and chemical warfare agent.
Topics: Amifostine; Animals; Antidotes; Antineoplastic Agents, Alkylating; Body Weight; Chemical Warfare Age | 2009 |
Studies on the radioprotective potency of amifostine on salivary glands of rats during fractionated irradiation: acute and late effects.
Topics: Acute Disease; Amifostine; Animals; Drug-Related Side Effects and Adverse Reactions; Male; Radiation | 2003 |
Time dependent protection of amifostine from renal and hematopoietic cisplatin induced toxicity.
Topics: Amifostine; Animals; Antineoplastic Agents; Blood Cell Count; Blood Urea Nitrogen; Cisplatin; Drug A | 2005 |